News Breaks |
|
|
| January 7, 2013 |
| 17:01 EDT |  | ENDP | Endo Health sees FY12 cash flow from operations of at least $600M
Endo Health continue to expect 2012 cash flow from operations of at least $600M. |
|
|
News For ENDP From The Last 14 Days Check below for free stories on ENDP the last two weeks. |
|
|
| May 17, 2013 |
| 11:53 EDT |  | ENDP | Options with decreasing implied volatility: SGMO ARNA CSC ENDP
 Subscribe for More Information |
|
| May 16, 2013 |
| 10:03 EDT |  | ENDP | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 08:27 EDT | | ENDP | Endo Health upgraded to Buy from Neutral at Buckingham
Buckingham upgraded Endo Health based on attractive risk/reward and expectations for a more detailed strategy from the new CEO, maybe by Q2 results. Price target remains $41. |
|
| May 13, 2013 |
| 09:27 EDT |  | ENDP | Endo Health downgraded to Market Perform from Outperform at William Blair
|
|
| 09:25 EDT | | ENDP | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 09:04 EDT |  | ENDP | Endo Health falls 4.8%
Endo Health is down 4.8%, or $1.67, to $33.30 |
|
| 08:13 EDT |  | ENDP | Endo Health price target lowered to $31 from $35 at Susquehanna
Subscribe for More Information |
|
| 07:49 EDT | | ENDP | FDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. |
|
| 07:45 EDT | | ENDP | Endo Health price target lowered to $36 from $42 at Stifel
Subscribe for More Information |
|
| 07:32 EDT | | ENDP | Endo Health downgraded to Sell from Neutral at Lazard Capital
Subscribe for More Information |
| |
| 07:20 EDT | | ENDP | Endo Health price target lowered to $37 from $47 at Jefferies
Jefferies lowered its price target for Endo Health after the FDA ruled that crushable Opana generics can come to market. The firm keeps a Buy rating on the stock, saying the company's spending flexibility is underappreciated. |
|
| 06:48 EDT | | ENDP | Endo Health downgraded to Fair Value from Buy at CRT Capital
Subscribe for More Information |
|
| May 10, 2013 |
| 16:59 EDT | | ENDP | Endo Health says FDA denial could cut FY13 adjusted EPS by 55c
Subscribe for More Information |
|
| 15:45 EDT | | ENDP | Endo Health trading halted, pending news
|
|
| 15:44 EDT | | ENDP | Endo Health denied petition to block Opana ER generics
Subscribe for More Information |
|
| May 9, 2013 |
| 16:52 EDT | | ENDP | BDSI's Phase 3 trials for BEMA Buprenorphine to finish late 2013 or early 2014
Subscribe for More Information |
|
| 16:44 EDT | | ENDP | Blue Ridge Capital reports 5.98% passive stake in Endo Health
Subscribe for More Information |
|
| May 8, 2013 |
| 10:00 EDT | | ENDP | On The Fly: Analyst Downgrade Summary
Subscribe for More Information |
|
| 08:40 EDT | | ENDP | Endo Health downgraded to Neutral from Buy at Buckingham
Subscribe for More Information |
|
| 07:01 EDT | | ENDP | Endo Health downgraded to Underperform from Neutral at Cowen
|
| |
|
|
|
|
